Ramon Diez-Feijóo Juan Jose Rodríguez-Sevilla Concepcion Fernández-Rodríguez Solange Flores Carmen Raya Ana Ferrer Luis Colomo Antonio Salar
10.3389/fimmu.2021.798251
Front Immunol
2022 Jan 10;12:798251.
waldenström’s macroglobulinemia agranulocytosis bendamustine immunoglobulin rituximab
CC BY
https://pubmed.ncbi.nlm.nih.gov/35082788/
Agranulocytosis / drug therapy Antineoplastic Combined Chemotherapy Protocols / adverse effects Immunoglobulins, Intravenous / therapeutic use
Agranulocytosis / drug therapy Antineoplastic Combined Chemotherapy Protocols / adverse effects Immunoglobulins, Intravenous / therapeutic use Case Reports Aged Agranulocytosis / chemically induced Agranulocytosis / immunology Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bendamustine Hydrochloride / administration & dosage Bendamustine Hydrochloride / adverse effects Dose-Response Relationship, Drug Humans Immunoglobulins, Intravenous / administration & dosage Male Rituximab / administration & dosage Rituximab / adverse effects Treatment Outcome Waldenstrom Macroglobulinemia / drug therapy Immunoglobulins, Intravenous Rituximab Bendamustine Hydrochloride
PMC8784545
35082788
Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine
2022